|
| | Straka et al. [5] | Javaud et al. [7] | Charmillon et al. [8] | Illing et al. [9] |
|
| Study type | Randomized controlled trial | Prospective observation study | Case report | Case report |
| Patients, | 3 | 1 | 1 | 1 |
| Characteristics | | | | |
| Gender | -- | -- | Female | Male |
| Age, years | -- | -- | 65 | 62 |
| Ethnicity | -- | -- | Caucasian | -- |
| Duration of ACEI therapy, months | -- | -- | -- | 60 |
| Symptoms | -- | -- | Tongue/facial swelling/severe dyspnea | Drooling/tongue swelling |
| Clinical course | | | | |
| Symptom onset to ED presentation | -- | -- | -- | -- |
| ED presentation to intubation, mins | -- | -- | -- | -- |
| ED presentation to icatibant | -- | -- | -- | -- |
| Icatibant administration | -- | After intubation | After intubation | Before intubation |
| Icatibant to first symptom resolution, hrs | -- | -- | 1 | “Slow resolution over 48 hours” |
| Hospital day/time to extubation from icatibant | -- | Day 2 | Day 3 | 48 hours |
| ED presentation to discharge | -- | -- | Day 3 | “A few days later” after extubation |
| Conclusion | No difference in number of intubated patients between groups or time to symptom resolution compared to placebo | Icatibant use for ACEI-induced angioedema elicits faster symptom relief than placebo | Icatibant recommended for bradykinin mediated angioedema | Icatibant does not always provide rapid and complete resolution of symptoms caused by angioedema |
|
| | Fok et al. [10] |
|
| Study type | Case series |
| Patients, | 4 |
| Characteristics | | | | |
| Gender | Female | Male | Female | Female |
| Age, years | 75 | 49 | 40 | 62 |
| Ethnicity | -- | -- | -- | -- |
| Duration of ACEI therapy | 20 years | 1 day | 2 days | 4 years |
| Symptoms | Lip/tongue swelling | Drooping/facial swelling | Sore throat/drooling | Tongue swelling/hoarse voice |
| Clinical course | | | | |
| Symptom onset to ED presentation, hrs | 1 | 24 | 6 | 2 |
| ED presentation to intubation, hrs | 2 | 2 | 1 | 14 |
| ED presentation to icatibant, hrs | 72 | 2 | 2 | 14 |
| Icatibant administration | After intubation | At time of intubation | Before intubation | At time of intubation |
| Icatibant to first symptom resolution, hrs | 7 | 3 | 3 | 2 |
| Hospital day/time to extubation from icatibant | Within 24 hours for 3 out of 4 patients |
| ED presentation to discharge | -- | -- | -- | -- |
| Conclusions | Icatibant is effective for adrenaline-unresponsive acute upper airway angioedema involving the larynx or oropharynx |
|
